News | SCAI | May 17, 2020

ISCHEMIA Trial: Patients With Intermediate Left Main Coronary Disease Have Worse Cardiovascular Events

ISCHEMIA Trial: Patients With Intermediate Left Main Coronary Disease Have Worse Cardiovascular Events. #SCAI2020

May 17, 2020 – A new study shows that when compared with patients without intermediate left main coronary artery disease, those with intermediate left main disease have greater risk of cardiovascular events. The findings of the ISCHEMIA trial sub study were presented during the Society for Cardiovascular Angiography and Interventions (SCAI) 2020 Virtual Conference  as featured clinical research.

“Our study showed that when compared with patients without intermediate left main disease, those with intermediate left main disease had worse outcomes,” said Sripal Bangalore, M.D., FSCAI, director of the cardiac catheterization laboratory at Bellevue Hospital and lead author of the study. “However, there was no treatment interaction such that the outcomes with invasive vs. conservative were similar whether or not the patient had intermediate left main disease on CCTA.”

The presence of left main disease (LMD) typically provokes both emotional and evidence-based concerns that apart from trials done in the 1980s, patients with left main disease have been excluded from trials of revascularization vs. medical therapy. ISCHEMIA also excluded patients with left main disease, although patients with intermediate left main disease (25-49%) were allowed. The outcomes of these patients and the effect of invasive vs. conservative strategy has not been explored before.

In the study, randomized ISCHEMIA trial participants who underwent coronary computed tomography angiography (CCTA) at baseline were categorized into those with (25-49%) and without (<25%) intermediate LMD as determined by a core lab. Patients with LMD ≥50%, those with prior coronary artery bypass graft surgery (CABG), and those with non-evaluable or missing data on LM stenosis were excluded. Both clinical and quality of life (QoL) outcomes in those with and without intermediate LMD were compared, as well as outcomes of participants randomized to an initial invasive versus conservative strategy.

ISCHEMIA randomized 5,179 participants to an initial invasive or conservative strategy; those who underwent coronary CCTA comprise the LMD sub study cohort. Among the 3,913 participants who underwent CCTA, 3,699 satisfied the inclusion criteria. Of these participants, 962 (26%) had intermediate LMD and 2,737 (74%) did not. Among invasive strategy participants with intermediate LMD, 7.0% had significant LM stenosis on invasive angiography. The primary outcome event rate was significantly higher in those with intermediate LMD as compared to those without intermediate LMD (adjusted HR=1.31; 95% CI 1.06 to 1.61; P=0.0123).

Find links to the rest of the SCAI late-breaking trials and other SCAI news
 

Related ISCHEMIA Trial Content:

ISCHEMIA Sub-study Shows Chest Pain, Stress Tests Warrant Attention Even If Arteries Are Clear

Sex Differences in Stress Test and CCTA Findings and Symptoms in the Ischemia Trial

ISCHEMIA Trial Results Find Interventions for Stable Heart Disease No better Than Drug Therapy

VIDEO: The Impact of the ISCHEMIA Trial on Cardiac Imaging
 


Related Content

News | Cardiac Diagnostics

September 15, 2022 - Happitech has announced the launch of its FastStart Research app. The Amsterdam-based digital ...

Home September 15, 2022
Home
Feature | Cardiac Diagnostics | by Kelly Patrick

Like most healthcare markets, the diagnostic cardiology market has had a bumpy ride in recent years. The COVID-19 ...

Home August 23, 2022
Home
Feature | Cardiac Diagnostics | By Adam Saltman, MD, PhD

Before opining on the future of cardiac health, I think it’s important to define what “cardiac health” actually is. If ...

Home May 04, 2022
Home
News | Cardiac Diagnostics

January 31, 2022 — Scientists have developed an artificial intelligence (AI) system that can analyze eye scans taken ...

Home January 31, 2022
Home
News | Cardiac Diagnostics

November 10, 2021 — Abbott released new global market research from its Beyond Intervention initiative, the company’s ...

Home November 10, 2021
Home
Feature | Cardiac Diagnostics | By Dave Fornell, DAIC Editor

October 29, 2021 — A new guideline for the evaluation and diagnosis of chest pain was released this week that provides ...

Home October 29, 2021
Home
News | Cardiac Diagnostics

October 4, 2021 – Nanowear, a hospital-at-home and remote diagnostic platform that used proprietary wearable cloth ...

Home October 04, 2021
Home
News | Cardiac Diagnostics

September 28, 2021 — Biotricity Inc., a medical diagnostic and consumer healthcare technology company, has developed a ...

Home September 28, 2021
Home
News | Cardiac Diagnostics

July 29, 2021 — A recent clinical study from Overlake Medical Center utilizing the Bardy Diagnostics Carnation ...

Home July 29, 2021
Home
News | Cardiac Diagnostics

July 1, 2021 — The U.S. Food and Drug Administration (FDA) has cleared the Angel Medical Systems Inc. second-generation ...

Home July 01, 2021
Home
Subscribe Now